Summary

39.22 -0.68(-1.69%)07/05/2024
Simulations Plus Inc. (SLP)

Key Facts


1 Day1 Week1 Month3 Months6 Months1 Year5 YearsAll Time
-1.69-16.67-13.143.19-7.70-9.8539.273,574.69


Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1


Trading Data
Close39.22
Open40.01
High40.06
Low38.58
Volume139,578
Change-0.68
Change %-1.69
Avg Volume (20 Days)112,610
Volume/Avg Volume (20 Days) Ratio1.24
52 Week Range32.86 - 52.69
Price vs 52 Week High-25.57%
Price vs 52 Week Low19.34%
Range-7.09
Gap Up/Down-5.06
Fundamentals
Market Capitalization (Mln)797
EBIDTA15,693,000
PE Ratio92.9615
PEG Ratio9.7712
WallStreet Target Price53.67
Book Value8.8590
Earnings Per Share0.5200
EPS Estimate Current Quarter0.1900
EPS Estimate Next Quarter0.0000
EPS Estimate Current Year0.6600
EPS Estimate Next Year0.8000
Diluted EPS (TTM)0.5200
Revenues
Profit Marging0.1626
Operating Marging (TTM)0.2427
Return on asset (TTM)0.0443
Return on equity (TTM)0.0616
Revenue TTM64,668,000
Revenue per share TTM3.2410
Quarterly Revenue Growth (YOY)0.1620
Quarterly Earnings Growth (YOY)0.0000
Gross Profit (TTM)43,084,000
Dividends
Dividend Share0.2400
Dividend Yield0.0050
Valuations
Trailing PE92.9615
Forward PE69.4444
Price Sales (TTM)0.0000
Price Book (MRQ)5.2514
Revenue Enterprise Value 12.7146
EBITDA Enterprise Value50.2492
Shares
Shares Outstanding19,984,900
Shares Float16,210,988
Shares Short0
Shares Short (Prior Month)0
Shares Ratio0.00
Short Outstanding (%)0.00
Short Float (%)0.11
Insider (%)18.79
Institutions (%)79.54


07/05 09:12 EST - marketbeat.com
Simulations Plus Stock Drops 15% Despite EPS Beat
Simulations Plus NASDAQ: SLP is a small-cap healthcare technology company with a value of about $800 million. The firm has vastly underperformed the market and its sector over the last 12 months, with a total return of -7%.
07/03 11:20 EST - zacks.com
Simulations Plus (SLP) Q3 Earnings & Revenues Beat Estimates
Simulations Plus' (SLP) fiscal third-quarter revenues are driven by strength in Software and Services units.
07/03 08:53 EST - benzinga.com
Simulations Plus Posts Q3 Results, Joins First Foundation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 0.2% on Wednesday.
07/02 19:28 EST - seekingalpha.com
Simulations Plus, Inc. (SLP) Q3 2024 Earnings Call Transcript
Simulations Plus, Inc. (NASDAQ:SLP ) Q3 2024 Earnings Conference Call July 2, 2024 5:00 PM ET Company Participants Lisa Fortuna - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer & Chief Operating Officer Conference Call Participants Christine Rains - William Blair François Brisebois - Oppenheimer & Company Matt Hewitt - Craig-Hallum David Larsen - BTIG Operator Greetings, and welcome to the Simulations Plus Third Quarter Fiscal 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
06/25 11:00 EST - zacks.com
Analysts Estimate Simulations Plus (SLP) to Report a Decline in Earnings: What to Look Out for
Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
06/20 08:30 EST - businesswire.com
Simulations Plus to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, will be participating in Morgan Stanley's 3rd Annual Life Sciences AI Summit on June 26, 2024, in New York City.
06/18 08:30 EST - businesswire.com
Simulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and Conference Call Date
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will report 3rd quarter FY24 earnings and host a conference call to discuss the financial results on July 2, 2024, at 5pm EDT.
06/14 13:06 EST - zacks.com
Simulations Plus (SLP) Upgraded to Buy: Here's Why
Simulations Plus (SLP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
06/13 10:33 EST - zacks.com
Simulations Plus (SLP) Buys Pro-ficiency Holdings for $100M
Simulation Plus (SLP) acquires Pro-ficiency from QHP Capital for $100 million in an all-cash transaction.
06/12 08:58 EST - businesswire.com
QHP Capital-Backed Pro-ficiency Acquired by Simulations Plus
RALEIGH, N.C.--(BUSINESS WIRE)--QHP Capital-Backed Pro-ficiency Acquired by Simulations Plus.
06/12 08:00 EST - businesswire.com
Simulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platform Spanning the Drug Development Continuum
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced the acquisition of Pro-ficiency with simulation-enabled solutions to expand and enhance the Company's offerings.
05/22 08:30 EST - businesswire.com
Simulations Plus to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, will be participating in Craig-Hallum's 21st Annual Institutional Investor Conference on May 29, in Minneapolis.
05/16 14:21 EST - zacks.com
Simulations Plus (SLP) Launches GPX to Advance PBPK Modeling
Simulations Plus (SLP) unveils GastroPlus X, which significantly reduces time spent on model setup, data management, and reformatting results.
05/15 08:30 EST - businesswire.com
Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the release of the completely redesigned GastroPlusX (GPX), the next generation PBPK/PBBM modeling & simulation software.
04/12 13:53 EST - investorplace.com
New AI Bot Predicts These 7 Stocks Will Mint Millionaires
You may have heard about GPT-4 Turbo, Gemini, Llama or X's (formerly Twitter) Grok. However, there is a new contender outside of these Big Tech models in town.
04/08 10:10 EST - zacks.com
Simulations Plus (SLP) DILIsym Software Licenses Renewed by FDA
For the seventh consecutive year, the FDA has renewed Simulations Plus' (SLP) license to the DILIsym software system for facilitating drug safety evaluations.
04/04 08:30 EST - businesswire.com
U.S. FDA Renews DILIsym® Software Licenses for 7th Year
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the US FDA has again renewed licenses to its DILIsym QST software to support informed decision-making in drug approvals.
04/04 07:36 EST - zacks.com
Simulations Plus (SLP) Q2 Earnings & Revenues Beat Estimates
Simulations Plus' (SLP) second-quarter fiscal 2024 top line is driven by higher revenues in the Software and Services business segments.
04/03 23:15 EST - seekingalpha.com
Simulations Plus, Inc. (SLP) Q2 2024 Earnings Call Transcript
Simulations Plus, Inc. (NASDAQ:SLP ) Q2 2023 Results Earnings Conference Call April 4, 2024 5:00 PM ET Company Participants Lisa Fortuna - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer and Chief Operating Officer Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group David Larsen - BTIG LLC François Brisebois - Oppenheimer & Co. Inc. Operator Greetings. And welcome to the Simulations Plus Second Quarter Fiscal 2024 Financial Results Conference Call.
04/03 18:21 EST - zacks.com
Simulations Plus (SLP) Q2 Earnings and Revenues Surpass Estimates
Simulations Plus (SLP) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.20 per share a year ago.